Show simple item record

dc.contributor.authorMcDonald, TJ
dc.contributor.authorBesser, RE
dc.contributor.authorPerry, M
dc.contributor.authorBabiker, T
dc.contributor.authorKnight, BA
dc.contributor.authorShepherd, MH
dc.contributor.authorEllard, S
dc.contributor.authorFlanagan, SE
dc.contributor.authorHattersley, AT
dc.date.accessioned2017-09-14T13:05:50Z
dc.date.issued2017-08-05
dc.description.abstractAIMS/HYPOTHESIS: The majority of infants with neonatal diabetes mellitus present with severe ketoacidosis at a median of 6 weeks. The treatment is very challenging and can result in severe neurological sequelae or death. The genetic defects that cause neonatal diabetes are present from birth. We aimed to assess if neonatal diabetes could be diagnosed earlier by measuring glucose in a dried blood spot collected on day 5 of life. METHODS: In this retrospective case-control study we retrieved blood spot cards from 11 infants with genetically confirmed neonatal diabetes (median age of diagnosis 6 [range 2-112] days). For each case we also obtained one (n = 5) or two (n = 6) control blood spot cards collected on the same day. Glucose was measured on case and control blood spot cards. We established a normal range for random glucose at day 5 of life in 687 non-diabetic neonates. RESULTS: All 11 neonates with diabetes had hyperglycaemia present on day 5 of life, with blood glucose levels ranging from 10.2 mmol/l to >30 mmol/l (normal range 3.2-6.0 mmol/l). In six of these neonates the diagnosis of diabetes was made after screening at day 5, with the latest diagnosis made at 16 weeks. CONCLUSIONS/INTERPRETATION: Neonatal diabetes can be detected on day 5 of life, preceding conventional diagnosis in most cases. Earlier diagnosis by systematic screening could lead to prompt genetic diagnosis and targeted treatment, thereby avoiding the most severe sequelae of hyperglycaemia in neonates.en_GB
dc.description.sponsorshipTJM is an NIHR HEE funded Clinical Senior Lecturer. SEF has a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (grant number: 105,636/Z/14/Z). ATH and SE are Wellcome Trust Senior Investigators. ATH is an NIHR Senior Investigator and MHS is supported by the NIHR Exeter Clinical Research Facility.en_GB
dc.identifier.citationPublished online 05 August 2017en_GB
dc.identifier.doi10.1007/s00125-017-4383-3
dc.identifier.urihttp://hdl.handle.net/10871/29340
dc.language.isoenen_GB
dc.publisherSpringer Verlagen_GB
dc.rightsOpen Access article distributed under the terms of the Creative Commons Attribution 4.0 International License CC-BYen_GB
dc.subjectBlood spotsen_GB
dc.subjectGlucoseen_GB
dc.subjectNeonatal diabetesen_GB
dc.subjectNewbornen_GB
dc.subjectScreeningen_GB
dc.titleScreening for neonatal diabetes at day 5 of life using dried blood spot glucose measurement.en_GB
dc.typeArticleen_GB
dc.date.available2017-09-14T13:05:50Z
dc.identifier.issn0012-186X
exeter.place-of-publicationGermanyen_GB
dc.descriptionThis is the author's accepted manuscripten_GB
dc.descriptionFinal version available from Springer via the DOI in this recorden_GB
dc.identifier.eissn1432-0428
dc.identifier.journalDiabetologiaen_GB
dc.identifier.pmid28779213
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/


Files in this item

This item appears in the following Collection(s)

Show simple item record

Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License CC-BY
Except where otherwise noted, this item's licence is described as Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License CC-BY